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and future trials should compare to real-world treatments wherever possible to
demonstrate clinically-meaningful differences.
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OBJECTIVES: Enhancements in renal transplant have led to reduced rates of acute
rejection leading to a shift to kidney function as an accepted endpoint in efficacy
trials. Characterizing long-term benefits requires modeling to project long-term
outcomes of treatment based on kidney function. The goal of this study was to
project rates of graft failure and quality adjusted life years over the lifetimes of
hypothetical patients receiving belatacept (a recently-introduced selective co-
stimulation blocker), cyclosporine or tacrolimus. METHODS: We developed a sim-
ulation with two phases that integrated trial-based information with a long-term
four-state Markov model (functioning graft, graft failure on dialysis, functioning
re-graft, and death). In the first phase, three-year distributions of patients in four
estimated glomerular filtration rate (eGFR) categories (60, 45-59, 30-44 and 15-29,
with graft failure assumed at eGFR 15 mLs/min/1.73m2) were estimated using a
mixed treatment comparison of cyclosporine, belatacept, and tacrolimus. The
Markov phase was populated using transplant recipient data from the United
States Renal Data System (n34,130). Utilities for adjusting life-years were ob-
tained from a study of US renal transplant patients. RESULTS: Over a 20-year
modeled time-horizon for 1,000 hypothetical patients, belatacept was associated
with 551 graft failures,and 9.6 quality-adjusted life years. Relative to cyclosporine,
belatacept was associated with 0.9 additional quality-adjusted life years, and 56
fewer graft failures. Relative to tacrolimus, belatacept was associated with 0.9 ad-
ditional quality-adjusted life years, and 18 fewer graft failures. CONCLUSIONS:
This is the first long-term follow-up model of renal transplant patients to be based
on trial-based graft function endpoints and include all relevant comparators. This
long-term extrapolation of differences in kidney function observed at three years
shows clinically important differences between treatments. While validation of
these models will require long-term follow-up of patients, modeling based on renal
function may prove to be a useful method of projecting long-term outcomes.
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BACKGROUND: Belatacept is a first in-class co-stimulation blocker developed for
primary maintenance immunosuppression following renal transplantation. Data
is widely available comparing belatacept to cyclosporine, limited data is available
comparing it with other immunosuppressants. OBJECTIVES: Estimate belatacept’s
efficacy and safety relative to tacrolimus. METHODS: A systematic review was
conducted of randomised controlled trials (RCTs) published between January 1990
and September 2010. Data extraction captured study duration, quality, baseline
data, treatment and clinical outcomes. Efficacy and safety outcomes included glo-
merular filtration rate (GFR), graft- and patient-survival, and acute rejection (AR).
The data were analysed with fixed- and random-effects models. Linear models
with outcome of mean difference were applied for GFR because GFR (ml/min) is a
continuous measure, unlike the other variables which are dichotomous in nature.
Logistic models were used for these other outcomes (summary measure being odds
ratios). Sensitivity analyses (SAs) were conducted based on trial durations and
sub-populations.RESULTS:We identified twenty-six RCTs comparing cyclosporine
with tacrolimus, three RCTs comparing cyclosporine with belatacept, and no trials
comparing tacrolimus with belatacept. Most trials were 12 months in duration
(range: 6 to 60 months). MTC results using 36 month belatacept data suggested
benefits with belatacept on patient survival (OR0.62 95%CI: 0.31,1.24), and differ-
ence in GFR (8.50 ml/min/1.73 m2; 95% CI ( 4.22,20.44), versus tacrolimus, with AR
outcomes favouring tacrolimus (OR2.43; 95%CI 1.08,5.34). MTC results indicated
reduced graft-survival with belatacept at 36 months (OR1.18 95%CI: 0.51,2.85).
However, SAs using data at 12 months post-transplant demonstrated a benefit for
belatacept on graft-survival (OR0.89 95%CI: 0.36,2.16). Benefits on graft-survival
were also seen at 12 and 24 months in the standard-criteria donor population. SAs
on the other outcomes resulted in similar conclusions to those of the base case.
CONCLUSIONS: Belatacept showed improved renal function and benefits in graft-
and patient-survival in comparison to tacrolimus despite increased risks for AR.
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract related to benign prostatic hypertrophy (BPH) using medical treat-
ment under actual conditions of use. METHODS: A pragmatic cohort of patients
treated medically, was followed up for 6 months, using validated questionnaires:
IPSS and MSF4. RESULTS: Fifty-one patients treated with Serenoa Repens (hexanic
extract) were evaluated, the mean age was 61.51 8.11 years, and on average the
diagnosis had been made 3.6 months previously.At 6 weeks, the IPSS was signifi-
cantly improved (p0.0001). This improvement in the IPSS score between 6 weeks
(10.155.36) and inclusion (13.766.03) was 3.6 points. An improvement was also
observed at 3 months. At 6 months, the p-value was also significant (p0.0001). The
improvement in the IPSS score between 6 months (6.903.46) and inclusion
(12.936.09) was 6 points.The MSF4 was unchanged. CONCLUSIONS: We observed
an improvement in the IPSS score from the sixth week; this statistical improve-
ment was confirmed by a significant clinical improvement in the sixth month.
Urinary/Kidney Disorders – Cost Studies
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OBJECTIVES: To analyze the cost savings after the consecutive introduction of the
generic immunospressants Azathioprine, Mycophenolic acid and Ciclosporin for
patients with transplanted kidney in Bulgaria. METHODS: Prospective observa-
tional study of the pharmacotherapy cost of patients after kidney transplantation
during 36 months (Mar 2008 – February 2011) was performed; 528 patients switched
to at least one of the generic immunosupressors were followed. Patients were
classified in 3 periods – beginning, during and after the switch. It was also followed
the changes in the whole pharmacotherapy as an indicator for switch compliance.
Mean cost per patient and cost saving were calculated. RESULTS: A total of 433
patients were treated with combined immunosuppressive therapy containing at
least one of the 4 originators (Imuran, Myfortic, Cellcept, Sandimmune) through
the Period 1 and then consecutively they increase to 528. Per patient cost of therapy
with the observed medications differs among the age groups and among the peri-
ods with low cost for age group of up to 70 years old. The introduction of generic
Azathioprine in 2009 reduced the mean pharmacotherapy cost for all patients with
6% from 4814 - 4539 BGN (2461 - 2321EUR). At the same time the introduction of
generic mycophenolic acid‘s derivates and appearance of generic ciclosporin in
2010 reduced the mean pharmacotherapy cost of the observed patients more than
2 times (119%) from 4539 – 2076 BGN (2321 – 1061 EUR). Total reduction of the mean
pharmacotherapy cost (Period 1 vs. Period 3) was 132% from 4814 – 2076 BGN (2461
– 1061 EUR). No other changes in the pharmacotherapy were observed, as well as no
back transfer to originator products. CONCLUSIONS: The introduction of generic
immunosuppressors significantly decreased the mean cost of therapy and let to
high cost savings for the hospital budget without any additional changes in the
patients’ pharmacotherapy.
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OBJECTIVES: To elucidate patient and economic burden associated with chronic
kidney disease (CKD) across countries. METHODS: A targeted literature review
using PubMed and desktop research was performed. Currency conversions were
adjusted to 2010. RESULTS: North American, European, and Asian studies were
identified; most reports were from the United States (US). Advanced CKD (stages
3-5) adversely affects outcomes. As patient-reported outcomes (PROs) deteriorate,
resource utilization (RU) and costs escalate. Across studies, patients with CKD
report cognitive impairment, dementia, sleep disturbance, and emotional and
physical dysfunction (PD), with PD being most pervasive. Compared with general
populations across countries, Health-related Quality of Life (HRQOL) and other
PROs decline in patients with CKD. Age, female gender, less education, lower in-
come, unemployment, limited exercise, and comorbid illness are predictors of re-
duced HRQOL. RU and costs to healthcare systems and employers increase with
CKD severity. Prior to (12-24 months) dialysis initiation, costs increase substan-
tially due to hospitalization. Annual US total cost per patient (c/p/p) with CKD
(stages 3-5) range from $6,026 (€4,927) to $30,398 (€24,855); annual Germany total
c/p/p (stages 1-4) is €3,581 ($4,379), compared to €1,272 ($1,555) in those without
CKD. The cost burden of CKD is rising. From 1993 to 2007, Medicare costs for pa-
tients with CKD increased by 5-fold. High healthcare costs (HC) and reduced
productivity due to CKD, burdens employers. For employees with CKD (US), HCs
range from $1,187 (€971) (stage 3) to $21,826 (€17,846) (stage 5) and work-hours
missed per week often exceeds 10. The impact of CKD on patient and economic
burden across countries is evident. CONCLUSIONS: Patient and economic burden
associated with CKD is considerable across countries. With disease progression
and kidney-function decline, unfavorable outcomes arise. As evidenced by the high
patient and economic burden of CKD, a large unmet need exists for new therapies
and employee CKD-management programs.
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OBJECTIVES: Evaluate if the use of Methoxy polyethylene-glycol erythropoietin
beta (MPG-beta) offers better health outcomes and costs with respect to erythro-
poietin beta multidose presentation (50,000 IU). METHODS: Analysis of incremen-
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